Advertisement

Topics

Latest "Global Replacement Implant Market Research Report Forecast 2017" News Stories

05:23 EDT 20th March 2019 | BioPortfolio

Here are the most relevant search results for "Global Replacement Implant Market Research Report Forecast 2017" found in our extensive news archives from over 250 global news sources.

More Information about Global Replacement Implant Market Research Report Forecast 2017 on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Global Replacement Implant Market Research Report Forecast 2017 for you to read. Along with our medical data and news we also list Global Replacement Implant Market Research Report Forecast 2017 Clinical Trials, which are updated daily. BioPortfolio also has a large database of Global Replacement Implant Market Research Report Forecast 2017 Companies for you to search.

Showing "Global Replacement Implant Market Research Report Forecast 2017" News Articles 1–25 of 53,000+

Wednesday 20th March 2019

WuXi Biologics Receives EMA GMP Certificates

WuXi Biologics to be the first biologics company in China approved by both the U.S. FDA and EMA SHANGHAI and WUXI, China, March 20, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announ...


Mundipharma Announces Launch of INVOKANA® and VOKANAMET® in Norway for the Treatment of Type 2 Diabetes as Part of Exclusive Distribution Agreement with Janssen

Invokana® and Vokanamet® are now available across the whole of Scandinavia, and in a total of 18 markets across Europe There is a significant patient need for new and effective diabetes treatment options, as the number of people with the condition in Europe is predicted to rise to 67 million by 20451 ...

Financière de Tubize SA : Convening of the ordinary and extraordinary meetings of shareholders of 24 April 2019

Financière de Tubize SA/NVAllée de la Recherche 601070 BrusselsBE 0403.216.429          www.financiere-tubize.be CONVENING OF THE ORDINARY AND EXTRAORDINARY GENERAL MEETINGS OF SHAREHOLDERS OF 24 APRIL 2019 The shareholders are invited to attend the ordinary and extraordinary general meetings, which will take place on Wednesday 24 April 2019 at respectively 11:00AM and 12:0...


4SC AG provides results for financial year 2018 and outlook

DGAP-News: 4SC AG / Key word(s): Annual Results 20.03.2019 / 07:30 The issuer is solely responsible for the content of this announcement. 4SC AG provides results for financial year 2018 and outlook Solid progress on advancing clinical pipeline Conference call scheduled for today, 20 March 2019, at 3:00 pm CET (10:00 am ET) Planegg-Martinsried, Germany, 20 March 2019 - 4SC AG (4SC,...

PAION AG REPORTS ON SUCCESSFUL FISCAL YEAR 2018

DGAP-News: PAION AG / Key word(s): Annual Results 20.03.2019 / 07:30 The issuer is solely responsible for the content of this announcement. PAION AG REPORTS ON SUCCESSFUL FISCAL YEAR 2018   - Remimazolam filings for market approval in China and Japan; U.S. will follow shortly - EU Phase III trial in general anesthesia started in July 2018 - Successful pre-submission meeting wi...

Probiodrug AG: Probiodrug and Alzheimer's Disease Cooperative Study (ADCS) Receive 15 Million USD National Institutes of Health (NIH) Grant for U.S. Phase 2b Core Program for PQ912

DGAP-News: Probiodrug AG / Key word(s): Miscellaneous 20.03.2019 / 07:00 The issuer is solely responsible for the content of this announcement. Probiodrug and Alzheimer's Disease Cooperative Study (ADCS) Receive 15 Million USD National Institutes of Health (NIH) Grant for U.S. Phase 2b Core Program for PQ912 Study to Evaluate Safety and Efficacy of Drug Seeking to Treat Those with Mild...

Mark Gonitzke, RPh, MBA, Former FDA Regulatory Reviewer, Office of Generic Drugs, Joins NDA Partners as Expert Consultant

NDA Partners Chairman Carl Peck, MD, announced today that Mark Gonitzke, RPh, MBA, a Registered Pharmacist with extensive experience in the development of generic drugs and drug/device combination products at FDA in the Center for Drug Evaluation and Research (CDER), has joined the firm as an Expert Consultant. ROCHELLE, Va. (PRWEB) March 20, 2019 NDA Partners Chairman Carl Peck, MD, announced to...

Synteract’s Continued Growth as a Leading CRO Results in Plans to Open Additional Office in Swansea, Wales

CRO now recruiting for biostats, data management and other positions Representatives from Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, will visit

Pasta and Noodles Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Pasta and Noodles report provides an independent information about the Pasta and Noodles industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent development.The r...

Canada budget overlooks basic research

I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

SHANGHAI, March 20, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, and German biopharma company MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR), today announced that the first pat...

Which pharmaceutical companies have the most implant dosed drugs?

This chart shows the pharmaceutical companies with the most implant dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most implant dosed drugs… The post Which pharmaceutical companies have the most impl... The post Which pharmaceutical companies have the most implant dosed drugs? appeared first on Biotechblog.

Tuesday 19th March 2019

Royal Holloway professors to lead new to research into curing Neurofibromatosis type 1

Linda Popplewell, Lecturer in Biomedical Sciences, and world-renowned Professor George Dickson, from the School of Biological Sciences, both at Royal Holloway, will lead a team looking for a treatment for NF1, a genetic disorder that causes tumors to form on nerve tissue.

Major scientific study of wound care dressings wins 'Best Clinical or Preclinical Research Award'

UNIVERSITY of Huddersfield researchers have taken part in an award-winning project that will enable healthcare companies to develop and supply more effective wound dressings.

Hurricane Energy (HUR) - Aoka Mizu hook-up at Lancaster

Edison Investment Research - Oil & gas - Hurricane Energy: The Aoku Mizu FPSO is now on station and hooked up at Lancaster; we believe this keeps the EPS on schedule for first oil in H119. Hurricane will now focus on topside commissioning prior to start-up, which will be followed by a ramp-up period to a gross targeted plateau production rate of 20kbd (17kbod net of operating efficiency). In addit...

Vermilion Energy (VET) - Dividend and growth comfortably covered

Edison Investment Research - Oil & gas - Vermilion Energy: Vermilion Energy offers a geographically diverse production base, the ability to fund an 8.1% dividend yield and a forecast FY19 c C$530m capital programme, all achievable even at realised commodity prices c 3% below our base case (WTI US$56.1/bbl, Brent US$62.8/bbl). We adjust our FY19 and FY20 forecasts to reflect lower short-term commod...

Women with undiagnosed diabetes in pregnancy more likely to experience stillbirths

Women who develop diabetes in pregnancy but are not diagnosed are much more likely to experience stillbirth than women without the condition, according to new research.

FDA warns two breast implant makers for failure to comply with post-approval study requirements

Today, the U.S. Food and Drug Administration issued warning letters to two breast implant manufacturers for failure to comply with their requirements, under their premarket approval orders, to conduct post-approval studies to assess the long-term safety and risks of their silicone gel-filled breast implants.

Group opposed to RCP assisted dying poll lacks transparency, claims report

The row over a poll on assisted dying being conducted by the Royal College of Physicians has reached a new level of acrimony, with claims that opposition to the poll is been orchestrated by...

Researchers develop new method to detect cancerous DNA in lung cancer patients’ blood: an advance in liquid biopsies

A new method of determining the sequence of molecules in DNA can be used to detect small fragments of cancerous genetic material in blood samples from lung cancer patients with a high degree of accuracy, according to new research published in the journal...

Set X6 w/ Stand Eppendorf Research Plus Pipettor 2.5,10,20,100,200,300M Pipettes

$795.00End Date: Thursday Apr-18-2019 15:36:13 PDTBuy It Now for only: $795.00Buy It Now | Add to watch list Biotech365 : Set X6 w/ Stand Eppendorf Research Plus Pipettor 2.5,10,20,100,200,300M Pipettes BioMarketplace You want to propose your products or a Biotech … Continue reading →

Opinion: “Global warming is the biggest public health threat of the 21st century and is going to change life on earth as we know it. It is an essential part of any 21st century medical school curriculum" https://buff.ly/2FmqKqd 

Opinion: “Global warming is the biggest public health threat of the 21st century and is going to change life on earth as we know it. It is an essential part of any 21st century medical school curriculum" https://buff.ly/2FmqKqd 

Scientists at @UBC and @McMasterU develop what could be new bone implant material: http://ow.ly/Rd0230o6zaz 

Scientists at @UBC and @McMasterU develop what could be new bone implant material: http://ow.ly/Rd0230o6zaz 

Raynauds Disease Treatment Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Raynauds Disease Treatment report provides an independent information about the Raynauds Disease Treatment industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent...

Brain power: fresh approaches to Alzheimer’s drug discovery

New alliances are learning from past mistakes and breaking down research barriers


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks